Devyser Diagnostics

Devyser Diagnostics Current Liabilities

The Current Liabilities of Devyser Diagnostics (DVYSR.ST) as of Oct 19, 2026 is 70.90 M SEK. In the previous year, Current Liabilities was 109.60 M SEK — a change of -35.31% (lower).

Current Liabilities

70.90 MSEK

YoY

-35.31%

Last updated:

Current Liabilities of Devyser Diagnostics is 2025 70.90 M SEK. Current Liabilities of Devyser Diagnostics was 2024 109.60 M SEK. It decreases by -35.31% lower compared to the previous year.

The Devyser Diagnostics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
15.03 M SEK
Jan 1, 2019
20.18 M SEK
Jan 1, 2020
38.18 M SEK
Jan 1, 2021
47.43 M SEK
Jan 1, 2022
74.28 M SEK
Jan 1, 2023
117.60 M SEK
Jan 1, 2024
109.60 M SEK
Jan 1, 2025
70.90 M SEK
The Devyser Diagnostics Current Liabilities history
YEARCurrent LiabilitiesYoY
70.90 MSEK-35.31%
109.60 MSEK-6.80%
117.60 MSEK+58.33%
74.28 MSEK+56.62%
47.43 MSEK+24.21%
38.18 MSEK+89.24%
20.18 MSEK+34.21%
15.03 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB is a biotechnology company based in Hagersten, Sweden, operating within the healthcare sector. The company focuses on the development, manufacturing, and sale of genetic testing kits for routine diagnostics. It went public via an IPO on December 10, 2021, and currently employs 96 full-time staff. Devyser Diagnostics' products are utilized for complex DNA testing in areas such as hereditary diseases, oncology, and post-transplantation monitoring, aiding in the diagnosis of genetic conditions and guiding targeted cancer treatments. The company has developed and launched nearly 30 products for routine diagnostic use, including the Devyser Thrombophilia assay and Devyser Resolution XY, which analyzes chromosomes X and Y. These products are distributed directly to end customers or through hired distributors, with sales extending to over 45 countries. The company's website is www.devyser.com, and it is listed on the Stockholm Stock Exchange under the ticker DVYSR.ST. Devyser Diagnostics AB operates with a clear focus on providing diagnostic solutions that support medical professionals in identifying and managing genetic-related health issues through advanced testing technologies. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

Current Liabilities of Devyser Diagnostics is 70.90 M SEK in 2025.

Current Liabilities of Devyser Diagnostics changed from 109.60 M SEK to 70.90 M SEK, representing a -35.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Devyser Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Devyser Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Devyser Diagnostics